Form 4: Lemaitre Vascular Inc. Executive Trent G. Kamke Reports Stock Option Exercises and Sales
SEC Form 4
Trent G. Kamke, Senior VP of Operations at Lemaitre Vascular Inc., reports exercising stock options and selling shares of common stock between March 12 and March 14, 2025.
Summary
- Trent G. Kamke, a Senior VP of Operations at Lemaitre Vascular Inc. (LMAT), filed a Form 4 detailing changes in beneficial ownership.
- On March 12, 2025, Kamke exercised options to acquire 2,009 shares of common stock at a price of $23.56 per share and sold 2,009 shares at $82.12.
- On March 13, 2025, Kamke sold 4,020 shares at a weighted average price of $79.589 and 500 shares at a weighted average price of $80.2514.
- On March 14, 2025, Kamke exercised options to acquire 1,353 shares at $35.48, 127 shares at $48.6, and 1,229 shares at $37.29.
- Following these transactions, Kamke directly owns 3,753 shares of common stock and holds options to purchase 6,200 more.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Insider trading activity is a common occurrence in publicly traded companies, and the reporting requirements are standardized by the SEC.
- Comparing the volume and frequency of insider transactions at Lemaitre Vascular to those of its competitors (e.g., Medtronic, Boston Scientific) can provide insights into relative management sentiment and stock valuation.
- The exercise of stock options and subsequent sale of shares is a typical wealth diversification strategy for executives.
Stakeholder Impact
- Shareholders may interpret the insider's stock sales as a signal, although option exercises and sales are often part of personal financial planning.
- The transactions have no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/19/2018 | Date of grant for stock options exercisable on 03/12/2025 |
| 12/20/2019 | Date of grant for stock options exercisable on 03/14/2025 |
| 12/02/2020 | Date of grant for stock options exercisable on 03/14/2025 |
| 12/11/2021 | Date of grant for stock options exercisable on 03/14/2025 |
| 03/12/2025 | Earliest transaction date; exercise of options and sale of shares |
| 03/13/2025 | Sale of shares |
| 03/14/2025 | Exercise of options |
| 03/14/2025 | Date of report |
| 12/19/2025 | Expiration date for stock options granted on 12/19/2018 |
| 12/20/2026 | Expiration date for stock options granted on 12/20/2019 |
| 12/02/2027 | Expiration date for stock options granted on 12/02/2020 |
| 12/11/2028 | Expiration date for stock options granted on 12/11/2021 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.